Works matching DE "IPRAGLIFLOZIN"

Results: 69
    1
    2
    3

    Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.

    Published in:
    Cardiovascular Diabetology, 2016, v. 15, p. 1, doi. 10.1186/s12933-016-0449-7
    By:
    • Tanaka, Atsushi;
    • Murohara, Toyoaki;
    • Taguchi, Isao;
    • Eguchi, Kazuo;
    • Suzuki, Makoto;
    • Kitakaze, Masafumi;
    • Sato, Yasunori;
    • Ishizu, Tomoko;
    • Higashi, Yukihito;
    • Yamada, Hirotsugu;
    • Nanasato, Mamoru;
    • Shimabukuro, Michio;
    • Teragawa, Hiroki;
    • Ueda, Shinichiro;
    • Kodera, Satoshi;
    • Matsuhisa, Munehide;
    • Kadokami, Toshiaki;
    • Kario, Kazuomi;
    • Nishio, Yoshihiko;
    • Inoue, Teruo
    Publication type:
    Article
    4

    Metabolomic analysis of serum samples from a clinical study on ipragliflozin and metformin treatment in Japanese patients with type 2 diabetes: Exploring human metabolites associated with visceral fat reduction.

    Published in:
    Pharmacotherapy, 2023, v. 43, n. 12, p. 1317, doi. 10.1002/phar.2884
    By:
    • Tsukagoshi‐Yamaguchi, Ayano;
    • Koshizaka, Masaya;
    • Ishibashi, Ryoichi;
    • Ishikawa, Ko;
    • Ishikawa, Takahiro;
    • Shoji, Mayumi;
    • Ide, Shintaro;
    • Ide, Kana;
    • Baba, Yusuke;
    • Terayama, Ryo;
    • Hattori, Akiko;
    • Takemoto, Minoru;
    • Ouchi, Yasuo;
    • Maezawa, Yoshiro;
    • Yokote, Koutaro
    Publication type:
    Article
    5

    The sodium–glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes.

    Published in:
    Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-05704-y
    By:
    • Okura, Tsuyoshi;
    • Fujioka, Yohei;
    • Nakamura, Risa;
    • Kitao, Sonoko;
    • Ito, Yuichi;
    • Anno, Mari;
    • Matsumoto, Kazuhisa;
    • Shoji, Kyoko;
    • Matsuzawa, Kazuhiko;
    • Izawa, Shoichiro;
    • Okura, Hiroko;
    • Ueta, Etsuko;
    • Kato, Masahiko;
    • Imamura, Takeshi;
    • Taniguchi, Shin-ichi;
    • Yamamoto, Kazuhiro
    Publication type:
    Article
    6
    7
    8
    9
    10
    11
    12
    13

    Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomized controlled study (PRIME‐V study)

    Published in:
    Diabetes, Obesity & Metabolism, 2019, v. 21, n. 8, p. 1990, doi. 10.1111/dom.13750
    By:
    • Koshizaka, Masaya;
    • Ishikawa, Ko;
    • Ishibashi, Ryoichi;
    • Maezawa, Yoshiro;
    • Sakamoto, Kenichi;
    • Uchida, Daigaku;
    • Nakamura, Susumu;
    • Yamaga, Masaya;
    • Yokoh, Hidetaka;
    • Kobayashi, Akina;
    • Onishi, Shunichiro;
    • Kobayashi, Kazuki;
    • Ogino, Jun;
    • Hashimoto, Naotake;
    • Tokuyama, Hirotake;
    • Shimada, Fumio;
    • Ohara, Emi;
    • Ishikawa, Takahiro;
    • Shoji, Mayumi;
    • Ide, Shintaro
    Publication type:
    Article
    14
    15

    Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus.

    Published in:
    Drug Discoveries & Therapeutics, 2019, v. 13, n. 6, p. 322, doi. 10.5582/ddt.2019.01085
    By:
    • Kaoru Sugimoto;
    • Ichiro Abe;
    • Midori Minezaki;
    • Yuichi Takashi;
    • Kentaro Ochi;
    • Hideyuki Fujii;
    • Hanako Ohishi;
    • Yuka Yamao;
    • Tadachika Kudo;
    • Kenji Ohe;
    • Makiko Abe;
    • Yasushi Ohnishi;
    • Tomohiro Shinagawa;
    • Shigeaki Mukoubara;
    • Kunihisa Kobayashi
    Publication type:
    Article
    16
    17
    18
    19

    Long‐term effects of ipragliflozin and pioglitazone on metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow‐up of a randomized, 24 week, active‐controlled trial: Effect of ipragliflozin in MASLD

    Published in:
    Journal of Diabetes Investigation, 2024, v. 15, n. 9, p. 1220, doi. 10.1111/jdi.14246
    By:
    • Ito, Daisuke;
    • Shimizu, Satoshi;
    • Haisa, Akifumi;
    • Yanagisawa, Shinnosuke;
    • Inoue, Kazuyuki;
    • Saito, Daigo;
    • Sumita, Takashi;
    • Yanagisawa, Morifumi;
    • Uchida, Yoshihito;
    • Inukai, Kouichi;
    • Shimada, Akira
    Publication type:
    Article
    20

    Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME‐V study).

    Published in:
    Journal of Diabetes Investigation, 2021, v. 12, n. 2, p. 200, doi. 10.1111/jdi.13340
    By:
    • Koshizaka, Masaya;
    • Ishikawa, Ko;
    • Ishibashi, Ryoichi;
    • Maezawa, Yoshiro;
    • Sakamoto, Kenichi;
    • Uchida, Daigaku;
    • Nakamura, Susumu;
    • Yamaga, Masaya;
    • Yokoh, Hidetaka;
    • Kobayashi, Akina;
    • Onishi, Shunichiro;
    • Kobayashi, Kazuki;
    • Ogino, Jun;
    • Hashimoto, Naotake;
    • Tokuyama, Hirotake;
    • Shimada, Fumio;
    • Ohara, Emi;
    • Ishikawa, Takahiro;
    • Shoji, Mayumi;
    • Ide, Shintaro
    Publication type:
    Article
    21
    22
    23

    Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open‐label study (SOAR‐KOBE Study).

    Published in:
    Journal of Diabetes Investigation, 2019, v. 10, n. 5, p. 1254, doi. 10.1111/jdi.13015
    By:
    • Miura, Hiroshi;
    • Sakaguchi, Kazuhiko;
    • Okada, Yuko;
    • Yamada, Tomoko;
    • Otowa‐Suematsu, Natsu;
    • So, Anna;
    • Komada, Hisako;
    • Hirota, Yushi;
    • Ohara, Takeshi;
    • Kuroki, Yasuo;
    • Hara, Kenta;
    • Matsuda, Tomokazu;
    • Kishi, Minoru;
    • Takeda, Akihiko;
    • Yokota, Kazuki;
    • Tamori, Yoshikazu;
    • Ogawa, Wataru
    Publication type:
    Article
    24

    Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.

    Published in:
    Journal of Diabetes Investigation, 2019, v. 10, n. 4, p. 1012, doi. 10.1111/jdi.12985
    By:
    • Inoue, Hideka;
    • Morino, Katsutaro;
    • Ugi, Satoshi;
    • Tanaka‐Mizuno, Sachiko;
    • Fuse, Keiko;
    • Miyazawa, Itsuko;
    • Kondo, Keiko;
    • Sato, Daisuke;
    • Ohashi, Natsuko;
    • Ida, Shogo;
    • Sekine, Osamu;
    • Yoshimura, Masahiro;
    • Murata, Kiyoshi;
    • Miura, Katsuyuki;
    • Arima, Hisatomi;
    • Maegawa, Hiroshi
    Publication type:
    Article
    25

    Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes.

    Published in:
    Journal of Diabetes Investigation, 2019, v. 10, n. 2, p. 429, doi. 10.1111/jdi.12913
    By:
    • Takahashi, Kiyohiko;
    • Cho, Kyu Yong;
    • Nakamura, Akinobu;
    • Miya, Aika;
    • Miyoshi, Arina;
    • Yamamoto, Chiho;
    • Nomoto, Hiroshi;
    • Niwa, Hirokatsu;
    • Takahashi, Kiyohito;
    • Manda, Naoki;
    • Kurihara, Yoshio;
    • Aoki, Shin;
    • Ito, Yoichi M;
    • Atsumi, Tatsuya;
    • Miyoshi, Hideaki
    Publication type:
    Article
    26
    27
    28
    29
    30
    31

    Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring.

    Published in:
    Journal of Diabetes Investigation, 2015, v. 6, n. 6, p. 699, doi. 10.1111/jdi.12370
    By:
    • Yamada, Kentaro;
    • Nakayama, Hitomi;
    • Yoshinobu, Satoko;
    • Kawano, Seiko;
    • Tsuruta, Munehisa;
    • Nohara, Masayuki;
    • Hasuo, Rika;
    • Akasu, Shoko;
    • Tokubuchi, Ichiro;
    • Wada, Nobuhiko;
    • Hirao, Saori;
    • Iwata, Shinpei;
    • Kaku, Hiroo;
    • Tajiri, Yuji
    Publication type:
    Article
    32
    33
    34
    35
    36

    Impact of baseline left ventricular ejection fraction and body mass index on the effect of 24-week Ipragliflozin treatment on left ventricular diastolic function in patients with type 2 diabetes and chronic kidney disease: insights from the PROCEED trial.

    Published in:
    Cardiovascular Diabetology, 2025, v. 24, n. 1, p. 1, doi. 10.1186/s12933-025-02745-1
    By:
    • Teragawa, Hiroki;
    • Tanaka, Atsushi;
    • Takahashi, Kanae;
    • Oshita, Chikage;
    • Uchimura, Yuko;
    • Kamei, Nozomu;
    • Hirai, Hiroyuki;
    • Shimabukuro, Michio;
    • Taguchi, Isao;
    • Okada, Yosuke;
    • Node, Koichi
    Publication type:
    Article
    37
    38
    39
    40
    41

    Comparison of Visceral Fat Reduction by Ipragliflozin and Metformin in Elderly Type 2 Diabetes Patients: Sub-Analysis of a Randomized-Controlled Study.

    Published in:
    Diabetes Therapy, 2021, v. 12, n. 1, p. 183, doi. 10.1007/s13300-020-00949-0
    By:
    • Koshizaka, Masaya;
    • Ishikawa, Ko;
    • Ishibashi, Ryoichi;
    • Takahashi, Sho;
    • Sakamoto, Kenichi;
    • Yokoh, Hidetaka;
    • Baba, Yusuke;
    • Ide, Shintaro;
    • Ide, Kana;
    • Ishikawa, Takahiro;
    • Onishi, Shunichiro;
    • Kobayashi, Kazuki;
    • Takemoto, Minoru;
    • Horikoshi, Takuro;
    • Shimofusa, Ryota;
    • Maezawa, Yoshiro;
    • Yokote, Koutaro
    Publication type:
    Article
    42
    43
    44
    45
    46
    47
    48
    49
    50